489 related articles for article (PubMed ID: 29605029)
1. Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging.
Kaise H; Shimizu F; Akazawa K; Hasegawa Y; Horiguchi J; Miura D; Kohno N; Ishikawa T
J Surg Res; 2018 May; 225():175-180. PubMed ID: 29605029
[TBL] [Abstract][Full Text] [Related]
2. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
6. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
[TBL] [Abstract][Full Text] [Related]
8. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A
Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes.
Menes TS; Golan O; Vainer G; Lerman H; Schneebaum S; Klausner J; Even-Sapir E
Clin Breast Cancer; 2016 Oct; 16(5):389-395. PubMed ID: 27282845
[TBL] [Abstract][Full Text] [Related]
10. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
[TBL] [Abstract][Full Text] [Related]
11. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
[TBL] [Abstract][Full Text] [Related]
12. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
14. Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
Zhu Q; Tannenbaum S; Kurtzman SH; DeFusco P; Ricci A; Vavadi H; Zhou F; Xu C; Merkulov A; Hegde P; Kane M; Wang L; Sabbath K
Breast Cancer Res; 2018 Jun; 20(1):56. PubMed ID: 29898762
[TBL] [Abstract][Full Text] [Related]
15. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
[TBL] [Abstract][Full Text] [Related]
16. Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy.
Narui K; Ishikawa T; Oba MS; Hasegawa Y; Kaise H; Kawate T; Yamada A; Yamada K; Suzuki Y; Niikura N; Kohno N; Kimoto T; Sugae S; Kosaka Y; Miyashita M; Okamura T; Shimizu D; Tanino H; Tanabe M; Morita S; Endo I; Tokuda Y
Surg Oncol; 2020 Dec; 35():447-452. PubMed ID: 33045629
[TBL] [Abstract][Full Text] [Related]
17. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
[TBL] [Abstract][Full Text] [Related]
19. Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment.
Bufi E; Belli P; Di Matteo M; Terribile D; Franceschini G; Nardone L; Petrone G; Bonomo L
Eur J Radiol; 2014 Sep; 83(9):1631-8. PubMed ID: 24938669
[TBL] [Abstract][Full Text] [Related]
20. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
